SAB Biotherapeutics announced that the Company will present new data on its fully-human polyclonal antibody platform's ability to maintain its efficacy against multiple variants of several highly mutating viruses at the Options for Control of Influenza (OPTIONS XI) conference, which is hosted by the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) in Belfast, Northern Ireland, from September 26-29, 2022. SAB will conduct an oral presentation, titled Efficacy and Safety of SAB-176, a Novel Anti-Type A and B Influenza Immunotherapeutic: A Phase 2a, Randomized, Double-Blind Trial in H1N1 Challenged Adults.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.72 USD | +5.02% | -25.07% | -60.44% |
20/05 | SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
06/05 | SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.44% | 2.51Cr | |
+12.30% | 12TCr | |
+12.15% | 11TCr | |
-8.14% | 2.34TCr | |
-1.69% | 2.18TCr | |
-10.60% | 1.81TCr | |
-41.25% | 1.67TCr | |
-15.33% | 1.6TCr | |
+5.80% | 1.4TCr | |
+28.03% | 1.17TCr |
- Stock Market
- Equities
- SABS Stock
- News SAB Biotherapeutics, Inc.
- SAB Biotherapeutics to Present New Data At Isirv Options Xi Conference on Sab-176 Phase 2A Influenza Trial and Sab-185’S Effectiveness Against Multiple Covid-19 Variants